Key facts
- It has raised $13.5M; the latest was Later Stage VC ($8.9M) in Jan 2025.
- Notable investors include Tech Incubator Program for Startup, Smilegate Investment, HG Initiative, Woori Venture Partners, K2 Investment Partners — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Nunaps
- ·The full record, as it builds
Funding rounds
No funding rounds for Nunaps are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nunaps
Developer of a digital therapeutics platform designed to identify target biomarkers and create new therapeutics to treat or manage neurological disorders. The company offers a software-based clinical platform with neuroscience-driven training programs, clinician monitoring tools, and data-guided therapy workflows, enabling healthcare providers and patients with neurological and cognitive impairments to access structured, digital care that supports recovery and long-term management.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2017
- Employees
- 30
- Website
- nunaps.com/
- Ownership
- Privately Held (backing)
Nunaps doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nunaps shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nunaps in its N-PORT filings yet. We sweep new filings monthly.